Can Praxbind Push Pradaxa Ahead?
This article was originally published in The Pink Sheet Daily
Executive Summary
Approval of antidote should give Boehringer Ingelheim’s anticoagulant a needed advantage in a tough market, but it has a short window before Portola’s Factor Xa antidote comes along.